molecules of the month


oral WT and F877L mut. AR inhibitor

completed Ph. I/II trial in mCPRC

no hepatotox. vs. bioactivated prior lead

J. Med. Chem., Jan. 20, 2021

Janssen R&D, Spring House, PA

Chemical structure of molecule JNJ-63576253 Androgen Receptor Antagonist
1 min read

The JNJ AR antagonist, JNJ-63576253, is a clinical molecule for prostate cancer that is active against both wild-type androgen receptor as well as the clinically relevant AR mutant, F877L. F887L is a devious resistance mechanism that transforms antagonists of AR into agonists. The parent compound from which 6253 is derived was found to be unacceptably hepatotoxic, which was suspected to be due to bioactivation of an electron rich phenyl ring. Replacing the phenyl ring with a pyridine, an often-effective strategy for mitigating bioactivation of aryl amines, led to the dramatically improved safety window observed for JNJ-63576253. JNJ-63576253/TRC-253 recently completed a Ph. I/II trial in mCRPC.

request a trial

Drug Hunter is commited to helping industry innovators make informed decisions. Premium members have access to our library of the latest stories in science, written by scientists.

Request a trial to access insights powering the pros in our industry.

already a member? log in: